inclusion criteria: 1. male or female participant aged 18 years and above at randomization. 2. healthy adult or adult with pre-existing medical conditions who is in a stable condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study. 3. female participant: 1. a female participant is eligible if the participant is a woman of non-childbearing potential, i.e., surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal. 2. if the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. highly effective methods of contraception include: i. implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine hormonal-releasing system ii. established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository iii. azoospermic partner (vasectomized or due to medical cause), provided the partner is the sole sexual partner of the female participant and the absence of sperm has been confirmed (from medical records/examination/history). c.have a negative pregnancy test 4. participant is willing and able to comply with all required study visits and follow-up required by this protocol. 5. participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.

inclusion criteria: 1. male or female participant aged 18 years and above at randomization. 2. healthy adult or adult with pre-existing medical conditions who is in a stable condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study. 3. female participant: 1. a female participant is eligible if the participant is a woman of non-childbearing potential, i.e., surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal. 2. if the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. highly effective methods of contraception include: i. implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine hormonal-releasing system ii. established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository iii. azoospermic partner (vasectomized or due to medical cause), provided the partner is the sole sexual partner of the female participant and the absence of sperm has been confirmed (from medical records/examination/history). c.have a negative pregnancy test 4. participant is willing and able to comply with all required study visits and follow-up required by this protocol. 5. participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.

inclusion criteria: male or female participant aged 18 years and above at randomization. healthy adult or adult with pre-existing medical conditions who is in a stable condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study. female participant: a female participant is eligible if the participant is a woman of non-childbearing potential, i.e., surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal. if the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. highly effective methods of contraception include: i. implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine hormonal-releasing system ii. established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository iii. azoospermic partner (vasectomized or due to medical cause), provided the partner is the sole sexual partner of the female participant and the absence of sperm has been confirmed (from medical records/examination/history). c.have a negative pregnancy test participant is willing and able to comply with all required study visits and follow-up required by this protocol. participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.

inclusion criteria: male or female participant aged 18 years and above at randomization. healthy adult or adult with pre-existing medical conditions who is in a stable condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study. female participant: a female participant is eligible if the participant is a woman of non-childbearing potential, i.e., surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal. if the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. highly effective methods of contraception include: i. implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine hormonal-releasing system ii. established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository iii. azoospermic partner (vasectomized or due to medical cause), provided the partner is the sole sexual partner of the female participant and the absence of sperm has been confirmed (from medical records/examination/history). c.have a negative pregnancy test participant is willing and able to comply with all required study visits and follow-up required by this protocol. participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.